AB0414 DRUG PERSISTENCE ON JANUS KINASE (JAK) INHIBITORS COMPARED TO BIOLOGIC DMARDs IN PATIENTS WITH RHEUMATOID ARTHRITIS: RETROSPECTIVE STUDY IN THE AUSTRALIAN POPULATION
Authors: L. Scheepers, G. Jones
Journal: Annals of the Rheumatic Diseases (2022)

Background In rheumatoid arthritis (RA) persistence on disease modifying anti-rheumatic drugs (DMARDs) can be interpreted as a composite measure of effectiveness, safety, and tolerability. There is limited data available on real-life use of the newest class of drugs, the Janus Kinase (JAK) inhibitors. JAK inhibitors are small-molecule treatments which are administered orally on a daily basis and offer a long-term option in RA treatment. Objectives To compare drug persistence on JAK inhibitors tofacitinib, baricitinib and upadacitinib to tumor necrosis factor-α (TNF) inhibitors and other DMARDs in RA patients in Australia. Methods A retrospective observational study was conducted among RA patients in the Australian Medicare Database (from January 2006 till October 2021), aged ≥18 and for whom a JAK inhibitor or biologic DMARDs were dispensed. Data were provided by the Australian Department of Health and Aging through PROSPECTION, an Australian healthcare consulting company. A deidentified 10% sample of the database was taken as a random representation of RA patients in Australia. Kaplan-Meier analysis was used to calculate drug persistence rates, defined as the time from treatment initiation until the date of the last dose when there had not been a script dispensed for 6 months; except for rituximab, where a 12-month gap was applied. Results Data from 5,455 patients were analysed. For all patients the 12-month persistence rates were 61% for JAK inhibitors (baricitinib, tofacitinib, upadacitinib), 62% for tocilizumab, 52% for TNF inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab), and 51% for abatacept. The JAK inhibitors baricitinib (64%) and upadacitinib (78%) were superior to tofacitinib (54%). Median treatment persistence for upadacitinib was not reached (n = 430); was 27.1 months for baricitinib and 15.2 months for tofacitinib. For TNF inhibitors, treatment persistence was 15.1 months for adalimumab, 14.1 months for certolizumab, 14.0 months for etanercept, 11.1 months for golimumab and 4.5 months for infliximab. Persistence rates on first-line JAK inhibitors were 70% for baricitinib and 57% for tofacitinib; persistence rates dropped to 63% for baricitinib and 47% for tofacitinib in the second-line setting. First-line persistence rates were 54% for TNF inhibitors and 65% for tocilizumab, rates were sustained for tocilizumab, but dropped to 48% for TNF inhibitors in the second-line setting. Conclusion This real-world data highlights that in an Australian clinical practice setting treatment persistence rates on 12 months on JAK inhibitors, in particular baricitinib and upadacitinib, were superior to TNF inhibitors, but not to tocilizumab. Suggesting that persistence rates might differ according to biologics mode of action and line of treatment. Table 1. Persistence rates at 12 months post treatment initiation All patients First line Second line JAK inhibitors Overall 61% (2155) 60% (616) 60% (554) Baricitinib 64% (537) 70% (158) 63% (124) Tofacitinib 54% (1188) 57% (441) 47% (294) Upadacitinib 78% (430) 28% (17) 84% (136) TNF inhibitors Overall 52% (6339) 54% (4227) 48% (1561) Adalimumab 55% (2710) 56% (2030) 48% (590) Certolizumab 51% (593) 54% (251) 47% (147) Etanercept 52% (2079) 55% (1354) 47% (623) Golimumab 49% (814) 49% (506) 47% (174) Infliximab 35% (143) 23% (86) 53% (27) Other DMARDs Abatacept 51% (952) 56% (263) 46% (310) Rituximab 49% (284) 41% (70) 65% (79) Tocilizumab 62% (1156) 65% (279) 65% (351) In brackets are number of patients. References [1]Hetland, M.L., et al., Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum, 2010 [2]Jones, G., et al., A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population. Int J Rheum Dis, 2018 Acknowledgements L. Scheepers receives funding from The Farrell Family Foundation. Disclosure of Interests Lieke Scheepers Grant/research support from: received the Competitive Grant Program Inflammation ASPIRE 2020 Rheumatology International Developed Markets from Pfizer, Employee of: worked as an Associate Director Epidemiology at the Medical Evidence Observational Research Department at AstraZeneca., Graeme Jones Speakers bureau: Received payment for a speakers bureau from Novartis